Publication: Clinical features and outcomes of Bacille Calmette-Guérin (BCG)-induced diseases following neonatal BCG Tokyo-172 strain immunization
dc.contributor.author | Rattanachai Rermruay | en_US |
dc.contributor.author | Supattra Rungmaitree | en_US |
dc.contributor.author | Sunsanee Chatpornvorarux | en_US |
dc.contributor.author | Chantapat Brukesawan | en_US |
dc.contributor.author | Orasri Wittawatmongkol | en_US |
dc.contributor.author | Keswadee Lapphra | en_US |
dc.contributor.author | Wanatpreeya Phongsamart | en_US |
dc.contributor.author | Nantaka Kongstan | en_US |
dc.contributor.author | Benjawan Khumcha | en_US |
dc.contributor.author | Kulkanya Chokephaibulkit | en_US |
dc.contributor.other | Faculty of Medicine, Siriraj Hospital, Mahidol University | en_US |
dc.date.accessioned | 2019-08-23T10:31:49Z | |
dc.date.available | 2019-08-23T10:31:49Z | |
dc.date.issued | 2018-06-27 | en_US |
dc.description.abstract | © 2018 Elsevier Ltd Background: Bacille Calmette-Guérin (BCG) vaccination at birth may cause mild and benign local adverse effects (AE). More serious AE are rarely reported. Objective: To describe clinical features and outcomes of BCG (Tokyo-172 strain)-induce diseases (BCG-ID) that required medical attention at a tertiary care center in Bangkok, Thailand. Method: We retrospectively reviewed medical records from January 2007 to December 2016 that were selected by ICD-10 codes. The inclusion criteria were the patients under 3 years of age who developed lymphadenitis, osteitis, or disseminated infections of which BCG was a possible pathogen. Cases were classified into suspected (clinically compatible without laboratory confirmation), probable (suspected cases with M. tuberculosis complex identified), and confirmed BCG-ID (probable cases with molecular confirmation of M. bovis BCG strain). Results: 95 children were identified; 57 (60.0%) were male, and the median age at presenting symptom was 3.5 (range: 0.6–28.7) months. Of these, 25 (26.3%) were suspected, 49 (51.6%) were probable, and 21 (22.1%) were confirmed BCG-ID. Overall, 87 (92%) children had regional lymphadenitis corresponding to the BCG site, 5 (5%) had osteitis, and 3 (3%) had disseminated BCG. Of those with lymphadenitis, average size was 2.2 (range 0.7–5) cm. in diameter and 53% (46/87) had pulmonary involvement. Five children with immunodeficiency; three had disseminated BCG and two had lymphadenitis. Eight (9.2%) patients with lymphadenitis underwent needle aspiration; 57 (65.5%) had surgical excision. All children with BCG osteitis underwent surgical intervention in combination with anti-tuberculosis treatment. One patient with osteitis experienced long-term leg length discrepancy. Conclusion: Regional lymphadenitis was the most common feature of BCG-ID requiring medical attention. That none of the BCG osteitis were immunocompromised hosts suggested the potential virulence of BCG in neonates. A systematic national surveillance and reporting system is needed to develop accurate estimates of population incidence and support development of effective vaccine policy. | en_US |
dc.identifier.citation | Vaccine. Vol.36, No.28 (2018), 4046-4053 | en_US |
dc.identifier.doi | 10.1016/j.vaccine.2018.05.098 | en_US |
dc.identifier.issn | 18732518 | en_US |
dc.identifier.issn | 0264410X | en_US |
dc.identifier.other | 2-s2.0-85047626257 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/45129 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047626257&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Immunology and Microbiology | en_US |
dc.subject | Medicine | en_US |
dc.subject | Veterinary | en_US |
dc.title | Clinical features and outcomes of Bacille Calmette-Guérin (BCG)-induced diseases following neonatal BCG Tokyo-172 strain immunization | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047626257&origin=inward | en_US |